Asia Pacific Breast Implants Market Size to Exceed USD 790.8 Mn by 2032

The Asia Pacific Breast Implants Market, estimated at USD 439.9 Mn in 2025, is expected to exhibit a CAGR of 8.74% and reach USD 790.8 Mn by 2032.

The industry is witnessing significant growth driven by rising demand for advanced, reliable, and cost-effective medical devices across diagnostic, therapeutic, and monitoring applications. Rapid advancements in device design, digital health integration, and adoption of minimally invasive technologies are reshaping the competitive landscape. Furthermore, supportive regulatory frameworks, increasing healthcare investments, and the growing focus on patient-centric care are expected to create new growth avenues for market players.

An increase in the prevalence of breast cancer in Japan is expected to drive the market over the forecast period. For instance, in December 2025, according to the data published by the National Center for Biotechnology Information, it was estimated that 17.6% of women developed breast cancer in the year 2025 in Japan. Furthermore, according to the same source, it was estimated that 92, 024 (8.9%) women developed breast cancer in the year 2025 in Japan.

Asia Pacific Breast Implants Market – Impact of Coronavirus (COVID-19) Pandemic

The COVID-19 pandemic and lockdowns in various countries across the globe have impacted the financial status of businesses across all sectors, including the private healthcare sector. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry, mainly due to strict lockdowns in several regions. Private healthcare is one such sector that has been impacted significantly by the COVID-19 pandemic.

Furthermore, healthcare providers were facing challenges in terms of additional manpower, equipment, consumables, and other resources, which were required to ensure safety in hospitals and provide treatment to patients with other diseases. This has impacted the overall healthcare sector negatively.

During the COVID-19 pandemic, the Asia Pacific breast implant market was significantly impacted due to an increase in the demand for treatment options for breast cancer and breast augmentation and a decrease in the supply of breast implants due to restrictions imposed by the government during COVID-19.

Moreover, the COVID-19 pandemic led to an increase in breast seroma related disorder among people suffering from COVID-19. For instance, in September 2025, according to an article published in the Korean Society of Plastic and Reconstructive Surgeons, it was discussed that COVID-19 infection is an immunocompromised patient can result in a plethora of multisystem dysfunction. Some patients who had breast implants in their chests and suffering with COVID–19 were observed suffering with the periprosthetic breast implant seromas had been postulated to be related to trauma, hematoma, subclinical infection, implant rupture, breast implant-associated anaplastic large cell lymphoma (BIAALCL). In addition to developing a late periprosthetic seroma after contracting COVID-19, reports of late seromas occurring right away after receiving COVID-19 vaccine have also been made. Both viral vector vaccines and mRNA vaccines fell under this category.

Asia Pacific Breast Implants Market : Key Developments

In July 2025, Motiva LLC, subsidiary of the Motiva USA LLC, a medical device company, based in Australia initiated a clinical trial study to evaluate the long-term effectiveness of the Motiva Implants Round and Round Ergonomix (MIRO). The Motiva LLC company carried out a post-marketing surveillance study to demonstrate the silent rupture rate and satisfaction of patients who underwent a primary and revision breast augmentation surgery with Motiva Implants, 3 to 10 years before enrollment.

In 2025, According to data from Ever Healthcare, medical treatment clinic, based in Thailand, nearly 1 million plastic surgery operations are being conducted every year in South Korea, exclusive of the inbound medical tourists. This ever-increasing visibility of plastic surgery can be credited to the low costs of breast implantation in the country compared to western nations.

Browse 20 Market Data Tables and 12 Figures spread through 159 Pages and in-depth TOC on “Asia Pacific Breast Implants Market ”- Forecast to 2032, by Product Type (Silicone Breast Implant and Saline Breast Implant), by Shape (Round Breast Implant and Anatomical Breast Implants), by Application (Cosmetic Surgery and Reconstructive Surgery), by End User (Hospitals and Cosmetic Clinics) and by Country (China, India, Japan, Australia, South Korea, ASEAN, and Rest of APAC))

To know the latest trends and insights prevalent in this market, click the link below:

https://www.coherentmarketinsights.com/market-insight/asian-breast-implants-market-1806

Key Takeaways of the Asia Pacific Breast Implants Market :

• The Asia Pacific breast implants market is expected to exhibit a CAGR of 8.74% during the forecast period due to an increasing research and development activities focusing on improving long-term safety and quality of life. For instance, in February 2025, Zhenqi Lu, based in Shanghai, China, in collaboration with Shanghai Jiao Tong University, based in China, initiated a clinical trial study for studying the effects of cosmetic care and breast augmentation on body image in young Chinese breast cancer patients receiving chemotherapy. The study design for this clinical trial was a prospective, 2-arm quasi-experimental study, comprising two groups: the controlled group and the interventional group. In order to avoid interference, the two groups of participants were recruited at different periods.
• Furthermore, in January 2025, First Affiliated Hospital of Zhejiang University, based in China, initiated a clinical trial study to search for options on the breast reconstruction timing and method after removal of polyacrylamide hydrogel.
• Among application, the cosmetic surgery segment is estimated to hold a dominant position in the Asia Pacific breast implants market over the forecast period, due to an increasing number of breast augumentation procedures. For instance, in December 2025, according to the data published by the National Center for Biotechnology Information, it was estimated that approximately  300,000 breast enlargement cosmetic surgeries took place in Asia Pacific region in the year 2025.
• Major players operating in the Asia Pacific Breast Implants Market include Allergan, Plc. (AbbVie Inc.), Mentor Worldwide LLC, GC Aesthetics Plc, Sientra, Inc., POLYTECH Health and Aesthetics GmBH, Establishment Labs S.A., Laboratories Arion, HanSBiomed Co. Ltd., Groupe Sebbin SAS, and GG Biotechnology Ltd.